Bioono - Medical & Health

Bioregulator DELLIN - is produced in the form of ampoules with odorless lyophilized powder. It is highly soluble in water. The ampoule contains 0.3 mg of the delta-sleep-inducing peptide DSIP and the rest is a specially selected mixture of glycine, turine, L-carnosine and pantel (an extract from reindeer antlers).

COMPLETE SOLUTION FOR YOUR NEUROLOGICAL PROBLEMS

Indications for the use of the DELLIN supplement:

In pediatric neurology and psychiatry:

Complex therapy of infantile cerebral palsy (ICP);

Complex therapy of autism syndromes;

Complex therapy of epilepsy

Benign childhood epilepsy with EEG peaks in the central temporal region

Pediatric epilepsy with paroxysmal EEG activity in the occipital region

Focal seizures of epilepsy without change of consciousness

Simple partial seizures progressing to secondary generalized seizures

Myoclonic epilepsy in early childhood neonatal seizures

Childhood epileptic absences (pycnolepsy)

Epilepsy with grand mal seizures

Complex therapy of organic brain lesions;

Traumatic brain injury (TBI), both in the acute period and at the stage of rehabilitation;

Syndrome of delayed neuropsychic development of a child (ZNPR), moreover, regardless of etiology;

Psycho-speech delay (PRS), as well as speech disorders associated with functional changes in the central nervous system (takhilalia, bradilalia, stuttering);

Active rehabilitation after surgical neurosurgical measures (brain cyst excision, stenting in case of hydrocephalus, removal of a hematoma or brain tumor, etc.);

Emotional and behavioral disorders, in childhood and adolescence, states of motor and sensory disinhibition, as well as CNS hyperexcitability syndromes;

Signs of a violation of social adaptation, against the background of a change in the environment of stay (area, team, environment);

Tiki;

Phobias.

In general neurology and psychiatry:
Complex therapy of acute cerebrovascular accident (ACC) - according to the ischemic and hemorrhagic type (both in the acute period and at the stage of early and late rehabilitation);

Transient cerebral ischemic attacks;

Diencephalic disorders and autonomic crises of various etiologies;

Vestibulo-ataxic syndromes;

Traumatic brain injury (TBI), both in the acute period and at the stage of early and late rehabilitation;

Complex therapy of epilepsy
Localized epilepsy (focal)

Symptomatic epilepsy

Epileptic syndromes with complex partial seizures

Generalized idiopathic epilepsy

Epileptic syndromes - Kozhevnikov's syndrome, seizures associated with the use of alcohol, the use of drugs, hormonal changes, sleep deprivation, exposure to stress factors.

Unspecified seizures of epilepsy

Small seizures of epilepsy (petitmal)

Grand mal seizures (grandmal)

Neurodegenerative diseases (NDD), including Alzheimer's disease and multiple sclerosis;

Rehabilitation after transferred encephalitis and meningo-encephalitis;

Diabetic and toxic polyneuropathy;

Correction of astheno-neurotic syndrome, including chronic fatigue syndrome;

Therapy of unipolar depressions (resistant depression, minor depression, atypical depression, postnatal depression, recurrent depression, dysthymia, cyclothymia, vital depressions without psychotic disorders);

Sleep disturbances (impaired falling asleep and maintaining sleep - insomnia, disorders in the form of increased drowsiness - hypersomnia, violation of the cyclical sleep and wakefulness - dyssomnia, obstructive sleep apnea syndrome);

Eliminates dependence on long-term sleeping pills;

Dementia (including vascular dementia and senile dementia);

Anxiety disorders and Phobias;

Correction of mental disorders and behavioral disorders associated with the use of psychoactive substances;

Rehabilitation of patients after surgical, compression effects on the brain;

Rehabilitation after tissue hypothermia, or as a result of chronic brain hypoxia (for example, a decrease in the perfusion capacity of blood vessels against the background of atherosclerotic changes).

In drug practice:
Relief of withdrawal symptoms and prevention of delirious conditions;

Prevention of primary pathological attraction to alcohol or narcotic products;

Restoration of genetically determined sensitivity of op**te receptors.

Courses for children under 14:

A course for children from 1 to 3 years old - 1 ampoule daily, in the morning, for 5-10 days, if necessary, repeat the course after a 10-15 day pause;
A course for children from 3 to 6 years old - 1 ampoule daily, in the morning, for 10-15 days, if necessary, repeat the course after a 10-15 day break;
A course for children from 6 to 14 years old - 1 ampoule daily, in the first half of the day, for 10-20 days the daily dose is 2 ampoules, and then 1 ampoule per day), after a 15-day pause, repeat the course of taking 1 ampoule daily for 10-15 days.